CD8A and cancer: Treatment with the SMOi vismodegib (22 patients) or sonidegib (one patient) for four weeks led to changes in the TME, characterized by increased levels of MHC-I expression in cancer cells and increased infiltration of CD4+ and CD8+ cells in the tumor.